PROTARA THERAPEUTICS INC's ticker is TARA and the CUSIP is 74365U107. A total of 34 filers reported holding PROTARA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,496,632 | -30.1% | 2,692,594 | 0.0% | 1.46% | -4.9% |
| Q2 2023 | $6,435,300 | -20.3% | 2,692,594 | 0.0% | 1.54% | -36.4% |
| Q1 2023 | $8,077,883 | +11.9% | 2,692,594 | 0.0% | 2.42% | -3.6% |
| Q4 2022 | $7,216,152 | -9.7% | 2,692,594 | -0.6% | 2.51% | -24.0% |
| Q3 2022 | $7,993,000 | -10.0% | 2,708,067 | +0.9% | 3.30% | -17.6% |
| Q2 2022 | $8,885,000 | -35.0% | 2,684,167 | +0.4% | 4.00% | -5.6% |
| Q1 2022 | $13,664,000 | -24.1% | 2,674,031 | +0.9% | 4.24% | +11.2% |
| Q4 2021 | $17,996,000 | +1.6% | 2,650,000 | +3.6% | 3.82% | +15.4% |
| Q3 2021 | $17,705,000 | -29.0% | 2,558,472 | 0.0% | 3.31% | -20.1% |
| Q2 2021 | $24,920,000 | -38.1% | 2,558,472 | 0.0% | 4.14% | -30.0% |
| Q1 2021 | $40,270,000 | -35.0% | 2,558,472 | 0.0% | 5.92% | -26.9% |
| Q4 2020 | $61,941,000 | +43.9% | 2,558,472 | 0.0% | 8.09% | -3.9% |
| Q3 2020 | $43,059,000 | -33.5% | 2,558,472 | +15.8% | 8.42% | -35.6% |
| Q2 2020 | $64,752,000 | – | 2,208,472 | – | 13.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 2,692,594 | $4,496,632 | 1.46% |
| Privium Fund Management (UK) Ltd | 119,730 | $201,146 | 0.16% |
| Ikarian Capital, LLC | 188,664 | $315,069 | 0.04% |
| Orbimed Advisors | 772,584 | $1,290,215 | 0.03% |
| Boxer Capital, LLC | 209,227 | $349,409 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 64,000 | $106,880 | 0.00% |
| Baker Brothers Advisors | 199,671 | $333,451 | 0.00% |
| BOOTHBAY FUND MANAGEMENT, LLC | 18,864 | $31,503 | 0.00% |
| TWO SIGMA INVESTMENTS, LP | 27,345 | $45,666 | 0.00% |
| OSAIC HOLDINGS, INC. | 100 | $167 | 0.00% |